# McEwen Inc.: financial statements, quarterly

MUX · NYSE · CIK 314203 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mux.md) · [Financials](/companies/mux/financials.md) · [Filings](/companies/mux/filings.md) · [Insiders](/companies/mux/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mux/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [38.4](/filings/0001558370-25-003017.md) | [58.7](/filings/0001558370-25-003017.md) | [41.2](/filings/0001104659-26-028705.md) | [47.5](/filings/0001104659-26-028705.md) | [52.3](/filings/0001104659-26-028705.md) | [33.5](/filings/0001104659-26-028705.md) | [35.7](/filings/0001104659-26-056349.md) | [46.7](/filings/0001104659-26-091284.md) | [50.5](/filings/0001104659-26-028705.md) | [64.6](/filings/0001104659-26-028705.md) | [74.0](/filings/0001104659-26-056349.md) | [59.2](/filings/0001104659-26-091284.md) |
| Cost of revenue | $m | [26.5](/filings/0001558370-24-014459.md) | not reported | [25.1](/filings/0001558370-25-006772.md) | [32.1](/filings/0001558370-25-010563.md) | [29.7](/filings/0001104659-25-107117.md) | not reported | [19.6](/filings/0001558370-25-006772.md) | [27.7](/filings/0001558370-25-010563.md) | [35.2](/filings/0001104659-25-107117.md) | not reported | not reported | not reported |
| Gross profit | $m | [3.8](/filings/0001558370-25-003017.md) | [13.1](/filings/0001558370-25-003017.md) | [6.0](/filings/0001104659-26-028705.md) | [10.8](/filings/0001104659-26-028705.md) | [13.8](/filings/0001104659-26-028705.md) | [0.4](/filings/0001104659-26-028705.md) | [10.1](/filings/0001104659-26-056349.md) | [12.3](/filings/0001104659-26-091284.md) | [7.8](/filings/0001104659-26-028705.md) | [17.4](/filings/0001104659-26-028705.md) | [31.5](/filings/0001104659-26-056349.md) | [20.1](/filings/0001104659-26-091284.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(28.8)](/filings/0001558370-24-014459.md) | [(47.4) d](/filings/0001104659-26-028705.md) | [(22.0)](/filings/0001558370-25-006772.md) | [(13.9)](/filings/0001558370-25-010563.md) | [(0.1)](/filings/0001104659-25-107117.md) | [(14.5) d](/filings/0001104659-26-028705.md) | [(7.6)](/filings/0001104659-26-056349.md) | [(3.4)](/filings/0001104659-26-091284.md) | [(8.4)](/filings/0001104659-25-107117.md) | [22.1 d](/filings/0001104659-26-028705.md) | [41.2](/filings/0001104659-26-056349.md) | [7.7](/filings/0001104659-26-091284.md) |
| Income tax | $m | [(0.2)](/filings/0001558370-24-014459.md) | [36.7 d](/filings/0001104659-26-028705.md) | [(2.6)](/filings/0001558370-25-006772.md) | [(2.4)](/filings/0001558370-25-010563.md) | [0.8](/filings/0001104659-25-107117.md) | [1.1 d](/filings/0001104659-26-028705.md) | [(1.1)](/filings/0001104659-26-056349.md) | [(1.1)](/filings/0001104659-26-091284.md) | [(1.3)](/filings/0001104659-25-107117.md) | [(24.0) d](/filings/0001104659-26-028705.md) | [(0.2)](/filings/0001104659-26-056349.md) | [(3.8)](/filings/0001104659-26-091284.md) |
| Net income | $m | [(18.5)](/filings/0001558370-25-003017.md) | [138](/filings/0001558370-25-003017.md) | [(20.4)](/filings/0001104659-26-028705.md) | [(13.0)](/filings/0001104659-26-028705.md) | [(2.1)](/filings/0001104659-26-028705.md) | [(8.2)](/filings/0001104659-26-028705.md) | [(6.3)](/filings/0001104659-26-028705.md) | [3.0](/filings/0001104659-26-091284.md) | [(0.5)](/filings/0001104659-26-028705.md) | [38.1](/filings/0001104659-26-028705.md) | [33.4](/filings/0001104659-26-056349.md) | [9.6](/filings/0001104659-26-091284.md) |
| Diluted EPS | $ per share | [(0.39)](/filings/0001558370-25-003017.md) | [2.89](/filings/0001558370-25-003017.md) | [(0.41)](/filings/0001104659-26-028705.md) | [(0.26)](/filings/0001104659-26-028705.md) | [(0.04)](/filings/0001104659-26-028705.md) | [(0.16)](/filings/0001104659-26-028705.md) | [(0.12)](/filings/0001104659-26-056349.md) | [0.06](/filings/0001104659-26-091284.md) | [(0.01)](/filings/0001104659-26-028705.md) | [0.57](/filings/0001104659-26-028705.md) | [0.47](/filings/0001104659-26-056349.md) | [0.14](/filings/0001104659-26-091284.md) |
| Basic EPS | $ per share | [(0.39)](/filings/0001558370-25-003017.md) | [2.89](/filings/0001558370-25-003017.md) | [(0.41)](/filings/0001104659-26-028705.md) | [(0.26)](/filings/0001104659-26-028705.md) | [(0.04)](/filings/0001104659-26-028705.md) | [(0.16)](/filings/0001104659-26-028705.md) | [(0.12)](/filings/0001104659-26-056349.md) | [0.06](/filings/0001104659-26-091284.md) | [(0.01)](/filings/0001104659-26-028705.md) | [0.70](/filings/0001104659-26-028705.md) | [0.56](/filings/0001104659-26-056349.md) | [0.16](/filings/0001104659-26-091284.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [49.1](/filings/0001558370-23-018256.md) | [23.0](/filings/0001104659-26-028705.md) | [22.0](/filings/0001558370-24-007329.md) | [40.7](/filings/0001558370-24-011396.md) | [29.2](/filings/0001558370-24-014459.md) | [13.7](/filings/0001104659-26-028705.md) | [68.5](/filings/0001558370-25-006772.md) | [53.6](/filings/0001558370-25-010563.md) | [51.2](/filings/0001104659-25-107117.md) | [51.0](/filings/0001104659-26-091284.md) | [56.5](/filings/0001104659-26-056349.md) | [78.9](/filings/0001104659-26-091284.md) |
| Current assets | $m | [126](/filings/0001558370-23-018256.md) | [52.7](/filings/0001558370-25-003017.md) | [52.0](/filings/0001558370-24-007329.md) | [72.2](/filings/0001558370-24-011396.md) | [59.6](/filings/0001558370-24-014459.md) | [41.2](/filings/0001104659-26-028705.md) | [106](/filings/0001558370-25-006772.md) | [108](/filings/0001558370-25-010563.md) | [119](/filings/0001104659-25-107117.md) | [108](/filings/0001104659-26-091284.md) | [110](/filings/0001104659-26-056349.md) | [130](/filings/0001104659-26-091284.md) |
| Total assets | $m | [573](/filings/0001558370-23-018256.md) | [657](/filings/0001558370-25-003017.md) | [639](/filings/0001558370-24-007329.md) | [645](/filings/0001558370-24-011396.md) | [668](/filings/0001558370-24-014459.md) | [665](/filings/0001104659-26-028705.md) | [731](/filings/0001558370-25-006772.md) | [736](/filings/0001558370-25-010563.md) | [748](/filings/0001104659-25-107117.md) | [820](/filings/0001104659-26-091284.md) | [973](/filings/0001104659-26-056349.md) | [992](/filings/0001104659-26-091284.md) |
| Current liabilities | $m | [53.5](/filings/0001558370-23-018256.md) | [30.0](/filings/0001558370-25-003017.md) | [37.9](/filings/0001558370-24-007329.md) | [43.0](/filings/0001558370-24-011396.md) | [50.9](/filings/0001558370-24-014459.md) | [47.7](/filings/0001104659-26-028705.md) | [45.3](/filings/0001558370-25-006772.md) | [45.9](/filings/0001558370-25-010563.md) | [56.8](/filings/0001104659-25-107117.md) | [63.8](/filings/0001104659-26-091284.md) | [96.7](/filings/0001104659-26-056349.md) | [63.7](/filings/0001104659-26-091284.md) |
| Total liabilities | $m | [139](/filings/0001558370-23-018256.md) | [155](/filings/0001558370-25-003017.md) | [156](/filings/0001558370-24-007329.md) | [160](/filings/0001558370-24-011396.md) | [166](/filings/0001558370-24-014459.md) | [170](/filings/0001104659-26-028705.md) | [251](/filings/0001558370-25-006772.md) | [251](/filings/0001558370-25-010563.md) | [259](/filings/0001104659-25-107117.md) | [274](/filings/0001104659-26-091284.md) | [321](/filings/0001104659-26-056349.md) | [285](/filings/0001104659-26-091284.md) |
| Long-term debt | $m | [40.0](/filings/0001558370-23-018256.md) | [40.0](/filings/0001558370-25-003017.md) | [40.0](/filings/0001558370-24-007329.md) | [40.0](/filings/0001558370-24-011396.md) | [40.0](/filings/0001558370-24-014459.md) | [40.0](/filings/0001104659-26-028705.md) | [126](/filings/0001558370-25-006772.md) | [126](/filings/0001558370-25-010563.md) | [126](/filings/0001104659-25-107117.md) | [126](/filings/0001104659-26-091284.md) | [123](/filings/0001104659-26-056349.md) | [121](/filings/0001104659-26-091284.md) |
| Current portion of debt | $m | not reported | not reported | [3.0](/filings/0001558370-24-007329.md) | [6.0](/filings/0001558370-24-011396.md) | [9.0](/filings/0001558370-24-014459.md) | not reported | not reported | not reported | not reported | not reported | [3.0](/filings/0001104659-26-056349.md) | [6.0](/filings/0001104659-26-091284.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | [12.0](/filings/0001558370-25-003017.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [434](/filings/0001558370-24-014459.md) | [502](/filings/0001104659-26-028705.md) | [483](/filings/0001558370-25-010563.md) | [485](/filings/0001104659-25-107117.md) | [502](/filings/0001104659-25-107117.md) | [495](/filings/0001104659-26-091284.md) | [480](/filings/0001104659-26-091284.md) | [484](/filings/0001104659-26-091284.md) | [489](/filings/0001104659-25-107117.md) | [546](/filings/0001104659-26-091284.md) | [652](/filings/0001104659-26-091284.md) | [707](/filings/0001104659-26-091284.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent, us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.3) d](/filings/0001558370-24-014459.md) | [16.1 d](/filings/0001104659-26-028705.md) | [3.9](/filings/0001558370-25-006772.md) | [3.6 d](/filings/0001558370-25-010563.md) | [23.2 d](/filings/0001104659-25-107117.md) | [(1.2) d](/filings/0001104659-26-028705.md) | [(1.9)](/filings/0001104659-26-056349.md) | [0.5 d](/filings/0001104659-26-091284.md) | [5.2 d](/filings/0001104659-25-107117.md) | [3.1 d](/filings/0001104659-26-028705.md) | [12.1](/filings/0001104659-26-056349.md) | [46.2 d](/filings/0001104659-26-091284.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [47.5](/filings/0001558370-25-003017.md) | [47.8](/filings/0001558370-25-003017.md) | [49.4](/filings/0001104659-26-028705.md) | [49.7](/filings/0001104659-26-028705.md) | [52.0](/filings/0001104659-26-028705.md) | [52.9](/filings/0001104659-26-028705.md) | [53.3](/filings/0001104659-26-056349.md) | [54.0](/filings/0001104659-26-091284.md) | [54.2](/filings/0001104659-26-028705.md) | [66.6](/filings/0001104659-26-028705.md) | [72.4](/filings/0001104659-26-056349.md) | [74.6](/filings/0001104659-26-091284.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 61,358,566 at 2026-08-05, from the cover of the [10-Q filed 2026-08-05](/filings/0001104659-26-091284.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. No prices; not investment advice.